Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer [2] (multiple letters)

Kadri Altundag, Ozden Altundag, Paolo Morandi, Mehmet Gunduz, Natasha M. Tiffany, Emily M. Wersinger, Tomasz M. Beer, Mark Garzotto

Research output: Contribution to journal › Letter › peer-review

Fingerprint

Dive into the research topics of 'Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer [2] (multiple letters)'. Together they form a unique fingerprint.